

Yasuhiro Ogura

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/367828/publications.pdf>

Version: 2024-02-01

170
papers

6,085
citations

70961

41
h-index

85405

71
g-index

171
all docs

171
docs citations

171
times ranked

4764
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of Neuromuscular Electrical Stimulation on Lower Limb Muscle Strength After Living Donor Liver Transplant: A Case-Control Study. <i>Transplantation Proceedings</i> , 2022, 54, 749-754.	0.3	2
2	Economy, Commerce, and Energy: How Do the Factors Influence Carbon Dioxide Emissions in Japan? An Application of ARDL Model. <i>Statistics, Politics, and Policy</i> , 2022, .	0.2	2
3	A novel anatomic variation of the intrahepatic biliary tree in live liver donor surgery: A case report. <i>International Journal of Surgery Case Reports</i> , 2021, 79, 231-233.	0.2	0
4	Temporal dynamics of the plasma microbiome in recipients at early post-liver transplantation: a retrospective study. <i>BMC Microbiology</i> , 2021, 21, 104.	1.3	5
5	The impact of chronic Epstein-Barr virus infection on the liver graft of pediatric liver transplant recipients: A retrospective observational study. <i>Transplant Infectious Disease</i> , 2021, 23, e13731.	0.7	1
6	Portal Vein Stenosis Following Liver Transplantation Hemodynamically Assessed with 4D-flow MRI before and after Portal Vein Stenting. <i>Magnetic Resonance in Medical Sciences</i> , 2021, 20, 231-235.	1.1	6
7	Psychosocial characteristics of alcoholic and non-alcoholic liver disease recipient candidates in liver transplantation: a prospective observational study. <i>BMC Gastroenterology</i> , 2021, 21, 449.	0.8	1
8	Laparoscopic Kasai portoenterostomy is advantageous over open Kasai portoenterostomy in subsequent liver transplantation. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2020, 34, 3375-3381.	1.3	12
9	Computational Fluid Dynamics-Based Blood Flow Assessment Facilitates Optimal Management of Portal Vein Stenosis After Liver Transplantation. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 460-461.	0.9	3
10	Limitation of non-transplant treatment and proper timing for liver transplantation in patients with hepatocellular carcinoma considering long-term survival. <i>Medicine (United States)</i> , 2020, 99, e21161.	0.4	3
11	De novo hepatocellular carcinoma in living donor liver grafts: A Japanese multicenter experience. <i>Hepatology Research</i> , 2020, 50, 1365-1374.	1.8	1
12	Decreased long-term graft survival in persistent biliary complications after right-lobe living-donor liver transplantation. <i>Clinical Transplantation</i> , 2020, 34, e13771.	0.8	7
13	The role of living donor liver transplantation for acute liver failure. <i>International Journal of Surgery</i> , 2020, 82, 145-148.	1.1	6
14	Policy as a "reporter" of RE component export or import? Evidence from PV/wind energy in OECD and BRICS. <i>Energy Economics</i> , 2020, 86, 104630.	5.6	14
15	Clinical Features and Long-Term Outcomes of Living Donors of Liver Transplantation Who Developed Psychiatric Disorders. <i>Annals of Transplantation</i> , 2020, 25, e918500.	0.5	8
16	1212. Temporal Dynamics of the Plasma Microbiome in Recipients at Early Post-liver Transplantation. <i>Open Forum Infectious Diseases</i> , 2020, 7, S627-S628.	0.4	0
17	Splenectomy in living donor liver transplantation and risk factors of portal vein thrombosis. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2019, 18, 337-342.	0.6	17
18	Budd-Chiari Syndrome Associated With Hypereosinophilic Syndrome Treated by Deceased-Donor Liver Transplantation: A Case Report. <i>Transplantation Proceedings</i> , 2019, 51, 3140-3146.	0.3	2

#	ARTICLE	IF	CITATIONS
19	Risk factors and long-term outcomes of pediatric liver transplant recipients with chronic high Epstein-Barr virus loads. <i>Transplant Infectious Disease</i> , 2018, 20, e12911.	0.7	8
20	Effect of herbal medicine daikenchuto on oral and enteral caloric intake after liver transplantation: A multicenter, randomized controlled trial. <i>Nutrition</i> , 2018, 54, 68-75.	1.1	9
21	Diagnostic Usefulness of APRI and FIB-4 for the Prediction of Liver Fibrosis After Liver Transplantation in Patients Infected with Hepatitis C Virus. <i>Transplantation Proceedings</i> , 2018, 50, 1431-1436.	0.3	16
22	Lung Metastases from Bile Duct Adenocarcinoma Mimicking Chronic Airway Infection and Causing Diagnostic Difficulty. <i>Internal Medicine</i> , 2018, 57, 1429-1432.	0.3	0
23	Brain death organ donor supported by a left ventricular assist device showing unexpected congestive liver fibrosis: A case report. <i>International Journal of Surgery Case Reports</i> , 2018, 47, 57-60.	0.2	4
24	Successful Blood Transfusion Management of a Living Donor Liver Transplant Recipient in the Presence of Anti-Jr a : A Case Report. <i>Transplantation Proceedings</i> , 2017, 49, 1604-1607.	0.3	0
25	Risk of alcohol use relapse after liver transplantation for alcoholic liver disease. <i>World Journal of Gastroenterology</i> , 2017, 23, 869.	1.4	11
26	Successful Post-Transplant Psychiatric Interventions During Long-Term Follow-Up of Patients Receiving Liver Transplants for Alcoholic Liver Disease. <i>American Journal of Case Reports</i> , 2017, 18, 1215-1219.	0.3	3
27	Donor Selection and Prophylactic Strategy for Venous Thromboembolic Events in Living Donors of Liver Transplantation Based on Results of Thrombophilia Screening Tests. <i>Annals of Transplantation</i> , 2017, 22, 409-416.	0.5	10
28	Fibrosing cholestatic hepatitis C in post-transplant adult recipients of liver transplantation. <i>Annals of Gastroenterology</i> , 2016, 29, 454-459.	0.4	19
29	Outcomes of Living Donor Liver Transplantation Alone for Patients on Maintenance Renal Replacement Therapy in Japan. <i>Transplantation Direct</i> , 2016, 2, e74.	0.8	5
30	Development of extensive inferior vena cava thrombosis due to the ligation of a large mesenteric-caval shunt during liver transplantation: A case report. <i>International Journal of Surgery Case Reports</i> , 2016, 29, 211-214.	0.2	4
31	Impact of human T-cell leukemia virus type 1 on living donor liver transplantation: a multicenter study in Japan. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2016, 23, 333-341.	1.4	16
32	How far can we lower graft-to-recipient weight ratio for living donor liver transplantation under modulation of portal venous pressure?. <i>Surgery</i> , 2016, 159, 1623-1630.	1.0	71
33	Living Donor Liver Transplantation Using a Liver Graft With Congenital Intrahepatic Portosystemic Shunt. <i>Transplantation Direct</i> , 2016, 2, e46.	0.8	3
34	Fibrosing Cholestatic Hepatitis in a Complicated Case of an Adult Recipient After Liver Transplantation: Diagnostic Findings and Therapeutic Dilemma. <i>American Journal of Case Reports</i> , 2016, 17, 597-604.	0.3	2
35	Cytomegalovirus (CMV) Monitoring After Liver Transplantation: Comparison of CMV Pp65 Antigenemia Assay with Real-Time PCR Calibrated to WHO International Standard. <i>Annals of Transplantation</i> , 2016, 21, 131-136.	0.5	15
36	Systemic hemodynamics in advanced cirrhosis: Concerns during perioperative period of liver transplantation. <i>World Journal of Hepatology</i> , 2016, 8, 1047.	0.8	19

#	ARTICLE	IF	CITATIONS
37	Early Conversion From Twice-Daily Tacrolimus to Prolonged-Release Tacrolimus in Liver Transplantation: A Single-Center Experience. <i>Annals of Transplantation</i> , 2016, 21, 448-455.	0.5	2
38	Successful adult-to-adult living donor liver transplantation using liver allograft after the resection of hemangioma: A suggestive case for a further expansion of living donor pool. <i>International Journal of Surgery Case Reports</i> , 2015, 16, 166-170.	0.2	6
39	Considerable Risk of Restenosis After Endoscopic Treatment for Hepaticojejunosomy Stricture After Living-Donor Liver Transplantation. <i>Transplantation Proceedings</i> , 2015, 47, 2493-2498.	0.3	11
40	Toxicokinetics of perfluoroalkyl carboxylic acids with different carbon chain lengths in mice and humans. <i>Journal of Occupational Health</i> , 2015, 57, 1-12.	1.0	45
41	Current status of deceased donor split liver transplantation in Japan. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2015, 22, 837-845.	1.4	10
42	Successful Living-Donor Liver Transplantation for Cholestatic Liver Failure Induced by Allopurinol: Case Report. <i>Transplantation Proceedings</i> , 2015, 47, 2778-2781.	0.3	3
43	Effectiveness and safety of immunization with live-attenuated and inactivated vaccines for pediatric liver transplantation recipients. <i>Vaccine</i> , 2015, 33, 1440-1445.	1.7	56
44	Postoperative Psychiatric Complications in Living Liver Donors. <i>Transplantation Proceedings</i> , 2015, 47, 1860-1865.	0.3	15
45	Changes in Surgical Site Infections after Living Donor Liver Transplantation. <i>PLoS ONE</i> , 2015, 10, e0136559.	1.1	17
46	Change of strategies and future perspectives against hepatitis B virus recurrence after liver transplantation. <i>World Journal of Gastroenterology</i> , 2015, 21, 10290.	1.4	14
47	Urinary Neutrophil Gelatinase-Associated Lipocalin: A Useful Biomarker for Tacrolimus-Induced Acute Kidney Injury in Liver Transplant Patients. <i>PLoS ONE</i> , 2014, 9, e110527.	1.1	36
48	How Do Transplant Surgeons Accomplish Optimal Portal Venous Flow During Living-Donor Liver Transplantation? Noninvasive Measurement of Indocyanine Green Elimination Rate. <i>Surgical Innovation</i> , 2014, 21, 43-51.	0.4	12
49	Plasma cell hepatitis induced by the termination of antiviral therapy for recurrent hepatitis C after living donor liver transplantation. <i>Hepatology Research</i> , 2014, 44, E279-83.	1.8	4
50	Hepatic arterial complications in adult living donor liver transplant recipients: a single-center experience of 673 cases. <i>Clinical Transplantation</i> , 2014, 28, 1025-1030.	0.8	40
51	Frequent incidence of escape mutants after successful hepatitis B vaccine response and stopping of nucleos(t)ide analogues in liver transplant recipients. <i>Liver Transplantation</i> , 2014, 20, 1211-1220.	1.3	21
52	Living Donor Liver Transplantation Using a Right Liver Graft With Additional Vein Reconstructions for Patient With Situs Inversus. <i>American Journal of Transplantation</i> , 2014, 14, 1453-1458.	2.6	8
53	Impact of preoperative uncontrollable hepatic hydrothorax and massive ascites in adult liver transplantation. <i>Surgery Today</i> , 2014, 44, 2293-2299.	0.7	12
54	Graft harvest of right posterior segment for living-donor liver transplantation. <i>International Journal of Surgery Case Reports</i> , 2014, 5, 516-522.	0.2	4

#	ARTICLE	IF	CITATIONS
55	Section 7. A New Therapeutic Strategy on Portal Flow Modulation That Increases Donor Safety With Good Recipient Outcomes. <i>Transplantation</i> , 2014, 97, S30-S32.	0.5	19
56	Living Donor Liver Transplantation. <i>Transplantation</i> , 2014, 97, S3.	0.5	42
57	Graft Reconditioning With Nitric Oxide Gas in Rat Liver Transplantation From Cardiac Death Donors. <i>Transplantation</i> , 2014, 97, 618-625.	0.5	20
58	Efficacy and safety of prophylaxis with entecavir and hepatitis B immunoglobulin in preventing hepatitis B recurrence after living donor liver transplantation. <i>Hepatology Research</i> , 2013, 43, 67-71.	1.8	37
59	Cytokine gene polymorphisms in acute cellular rejection following living donor liver transplantation: analysis of 155 donor-recipient pairs. <i>Hepatology International</i> , 2013, 7, 916-922.	1.9	4
60	Living donor liver transplantation for Budd-Chiari syndrome with hepatic inferior vena cava obstruction after open pericardial procedures. <i>Surgery Today</i> , 2013, 43, 1180-1184.	0.7	11
61	Impact of Sarcopenia on Survival in Patients Undergoing Living Donor Liver Transplantation. <i>American Journal of Transplantation</i> , 2013, 13, 1549-1556.	2.6	335
62	Impact of glutathione S-transferase T1 gene polymorphisms on acute cellular rejection in living donor liver transplantation. <i>Transplant Immunology</i> , 2013, 28, 14-17.	0.6	8
63	Pretransplant Serum Hepatitis C Virus RNA Levels Predict Response to Antiviral Treatment after Living Donor Liver Transplantation. <i>PLoS ONE</i> , 2013, 8, e58380.	1.1	1
64	Splenectomy Does Not Offer Immunological Benefits in ABO-Incompatible Liver Transplantation With a Preoperative Rituximab. <i>Transplantation</i> , 2012, 93, 99-105.	0.5	73
65	Use of Recipient's Left Colic Artery for Arterial Reconstruction During Liver Transplantation in Alagille Syndrome With Vasculopathy. <i>Transplantation</i> , 2012, 93, e20-e21.	0.5	3
66	Pediatric Liver Transplantation Using Reduced and Hyper-Reduced Left Lateral Segment Grafts: A 10-Year Single-Center Experience. <i>American Journal of Transplantation</i> , 2012, 12, 3406-3413.	2.6	47
67	Left-sided grafts for living-donor liver transplantation and split grafts for deceased-donor liver transplantation: Their impact on long-term survival. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2012, 36, 47-52.	0.7	7
68	Pre- and perioperative factors affecting infection after living donor liver transplantation. <i>Nutrition</i> , 2012, 28, 1104-1108.	1.1	68
69	Standard hepatic vein reconstruction with patch plasty using the native portal vein in adult living donor liver transplantation. <i>Liver Transplantation</i> , 2012, 18, 602-607.	1.3	19
70	Effects of Posttransplant Enteral Nutrition with an Immunomodulating Diet Containing Hydrolyzed Whey Peptide after Liver Transplantation. <i>World Journal of Surgery</i> , 2012, 36, 1666-1671.	0.8	39
71	Effect of maintenance therapy with low-dose peginterferon for recurrent hepatitis C after living donor liver transplantation. <i>Journal of Viral Hepatitis</i> , 2012, 19, 32-38.	1.0	4
72	Non-inflammatory centrilobular sinusoidal fibrosis in pediatric liver transplant recipients under tacrolimus withdrawal. <i>Hepatology Research</i> , 2012, 42, 895-903.	1.8	46

#	ARTICLE	IF	CITATIONS
73	Living donor liver transplantation for recurrent hepatocellular carcinoma after liver resection. <i>Surgery</i> , 2012, 151, 55-60.	1.0	25
74	How transplant surgeons can overcome the inevitable insufficiency of allograft size during adult living donor liver transplantation: strategy for donor safety with a smaller size graft and excellent recipient results. <i>Clinical Transplantation</i> , 2012, 26, E324-34.	0.8	32
75	Liver transplantation for severe hepatitis in patients with common variable immunodeficiency. <i>Pediatric Transplantation</i> , 2012, 16, E210-6.	0.5	22
76	Significance of trough monitoring for tacrolimus blood concentration and calcineurin activity in adult patients undergoing primary living-donor liver transplantation. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 259-266.	0.8	17
77	Lower Limit of the Graft-to-Recipient Weight Ratio Can Be Safely Reduced to 0.6% in Adult-to-Adult Living Donor Liver Transplantation in Combination with Portal Pressure Control. <i>Transplantation Proceedings</i> , 2011, 43, 2391-2393.	0.3	80
78	<i>De novo</i> activation of HBV with escape mutations from hepatitis B surface antibody after living donor liver transplantation. <i>Antiviral Therapy</i> , 2011, 16, 479-487.	0.6	29
79	Progressive familial intrahepatic cholestasis: a single-center experience of living donor liver transplantation during two decades in Japan. <i>Clinical Transplantation</i> , 2011, 25, 776-785.	0.8	46
80	Pediatric orthotopic living donor liver transplantation cures pulmonary hypertension caused by Abernethy malformation type Ib. <i>Pediatric Transplantation</i> , 2011, 15, e47-52.	0.5	17
81	A Rare Variation of the Biliary Tree of Relevance to Live Liver Donation. <i>American Journal of Transplantation</i> , 2011, 11, 869-870.	2.6	2
82	Supradiaphragmatic Approach for Budd-Chiari Syndrome with Transjugular Intrahepatic Portosystemic Shunt Stent in Combination with Inferior Vena Cava Reconstruction during Living Donor Liver Transplantation: A Case Report. <i>Transplantation Proceedings</i> , 2011, 43, 2093-2096.	0.3	11
83	Recurrence of Hepatocellular Carcinoma after Living Donor Liver Transplantation: What is the Current Optimal Approach to Prevent Recurrence?. <i>World Journal of Surgery</i> , 2011, 35, 1355-1359.	0.8	4
84	Thrombotic microangiopathy-like disorder after living-donor liver transplantation: A single-center experience in Japan. <i>World Journal of Gastroenterology</i> , 2011, 17, 1848.	1.4	19
85	Liver Transplantation for Congenital Biliary Dilatation. <i>Japanese Journal of Gastroenterological Surgery</i> , 2011, 44, 1219-1230.	0.0	0
86	The Rare Insertion of B4 With Trifurcated Portal Vein in Live Donor. <i>Transplantation</i> , 2010, 89, 1163-1164.	0.5	3
87	Surgery-Related Morbidity in Living Donors for Liver Transplantation. <i>Transplantation</i> , 2010, 89, 1276-1282.	0.5	118
88	Does a positive lymphocyte cross-match contraindicate living-donor liver transplantation?. <i>Surgery</i> , 2010, 147, 840-844.	1.0	37
89	Long-Term Outcomes After Living-Donor Liver Transplantation for Alagille Syndrome: A Single Center 20-Year Experience in Japan. <i>American Journal of Transplantation</i> , 2010, 10, 1951-1952.	2.6	11
90	Can children catch-up growth after living-donor liver transplantation?. <i>Liver Transplantation</i> , 2010, 16, NA-NA.	1.3	10

#	ARTICLE	IF	CITATIONS
91	Portal pressure ≤ 15 mm Hg is a key for successful adult living donor liver transplantation utilizing smaller grafts than before. <i>Liver Transplantation</i> , 2010, 16, 718-728.	1.3	202
92	Hepatic venous outflow obstruction in pediatric living donor liver transplantation using left-sided lobe grafts: Kyoto university experience. <i>Liver Transplantation</i> , 2010, 16, 1207-1214.	1.3	57
93	Posttransplant bacteremia in adult living donor liver transplant recipients. <i>Liver Transplantation</i> , 2010, 16, 1379-1385.	1.3	96
94	Fatal impact of lymphocyte cross-matching upon humoral rejection after adult living related liver transplantation. <i>Transplant International</i> , 2010, 23, 338-340.	0.8	9
95	Successful treatment of pulmonary hypertension secondary to congenital extrahepatic portocaval shunts (Abernethy type 2) by living donor liver transplantation after surgical shunt ligation. <i>Transplant International</i> , 2010, 23, 105-109.	0.8	26
96	Pediatric living-donor liver transplantation for acute liver failure: analysis of 57 cases. <i>Transplant International</i> , 2010, 23, 823-830.	0.8	24
97	Herpes simplex virus hepatitis after pediatric liver transplantation. <i>Transplant Infectious Disease</i> , 2010, 12, 353-357.	0.7	4
98	Hashimoto's encephalopathy after interferon therapy for hepatitis C virus in adult liver transplant recipient accompanied by post-transplant lymphoproliferative disorder related to Epstein-Barr virus infection. <i>Transplant Infectious Disease</i> , 2010, 12, 347-352.	0.7	11
99	Comprehensive and innovative techniques for liver transplantation in rats: A surgical guide. <i>World Journal of Gastroenterology</i> , 2010, 16, 3120.	1.4	48
100	Liver Transplantation for Congenital Biliary Dilatation: A Single-Center Experience. <i>Digestive Surgery</i> , 2010, 27, 492-501.	0.6	14
101	Graft Loss and Poor Outcomes After Living-Donor Liver Transplantation Owing to Arterioportal Shunts Caused by Liver Needle Biopsies. <i>Transplantation Proceedings</i> , 2010, 42, 2642-2644.	0.3	5
102	Impact of pretransplant nutritional status in patients undergoing liver transplantation. <i>Hepato-Gastroenterology</i> , 2010, 57, 1489-92.	0.5	22
103	Impact of enteral nutrition using a new immuno-modulating diet after liver transplantation. <i>Hepato-Gastroenterology</i> , 2010, 57, 1522-5.	0.5	15
104	Impact of Intestinal CYP2C19 Genotypes on the Interaction between Tacrolimus and Omeprazole, but Not Lansoprazole, in Adult Living-Donor Liver Transplant Patients. <i>Drug Metabolism and Disposition</i> , 2009, 37, 821-826.	1.7	38
105	Absence of Influence of Concomitant Administration of Rabepazole on the Pharmacokinetics of Tacrolimus in Adult Living-donor Liver Transplant Patients: A Case-control Study. <i>Drug Metabolism and Pharmacokinetics</i> , 2009, 24, 458-463.	1.1	10
106	Significance of Des-Gamma-Carboxy Prothrombin in Selection Criteria for Living Donor Liver Transplantation for Hepatocellular Carcinoma. <i>American Journal of Transplantation</i> , 2009, 9, 2362-2371.	2.6	152
107	MDR1 Haplotypes Conferring an Increased Expression of Intestinal CYP3A4 Rather than MDR1 in Female Living-Donor Liver Transplant Patients. <i>Pharmaceutical Research</i> , 2009, 26, 1590-1595.	1.7	18
108	Impact of Preexisting Circulating Effector T cells on the Outcome of ABO-Incompatible Adult LDLT. <i>Digestive Diseases and Sciences</i> , 2009, 54, 2253-2263.	1.1	6

#	ARTICLE	IF	CITATIONS
109	Mesorenal shunt using inferior mesenteric vein and left renal vein in a case of LDLT. <i>Transplant International</i> , 2009, 22, 1189-1192.	0.8	9
110	The impact of meticulous management for hepatic artery thrombosis on long-term outcome after pediatric living donor liver transplantation*. <i>Clinical Transplantation</i> , 2009, 23, 392-399.	0.8	53
111	Successful stent placement for hepatic venous outflow obstruction in pediatric living donor liver transplantation, including a case series review. <i>Pediatric Transplantation</i> , 2009, 13, 507-511.	0.5	21
112	Resolution of Preoperative Portal Vein Thrombosis After Administration of Antithrombin III in Living Donor Liver Transplantation: Case Report. <i>Transplantation Proceedings</i> , 2009, 41, 3931-3933.	0.3	10
113	Long-Term Outcomes for 32 Cases of Wilson's Disease After Living-Donor Liver Transplantation. <i>Transplantation</i> , 2009, 87, 261-267.	0.5	63
114	The technical pitfalls of duct-to-duct biliary reconstruction in pediatric living-donor left-lobe liver transplantation: The impact of stent placement. <i>Pediatric Transplantation</i> , 2008, 12, 661-665.	0.5	21
115	Portal Vein Complications in Pediatric Living Donor Liver Transplantation Using Left-Side Grafts. <i>American Journal of Transplantation</i> , 2008, 8, 2097-2105.	2.6	114
116	Relation between mRNA Expression Level of Multidrug Resistance 1/ABCB1 in Blood Cells and Required Level of Tacrolimus in Pediatric Living-Donor Liver Transplantation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 325, 610-616.	1.3	16
117	Required Transient Dose Escalation of Tacrolimus in Living-Donor Liver Transplant Recipients with High Concentrations of a Minor Metabolite M-II in Bile. <i>Drug Metabolism and Pharmacokinetics</i> , 2008, 23, 313-317.	1.1	15
118	Interaction between Tacrolimus and Lansoprazole, but not Rabeprazole in Living-Donor Liver Transplant Patients with Defects of CYP2C19 and CYP3A5. <i>Drug Metabolism and Pharmacokinetics</i> , 2008, 23, 134-138.	1.1	29
119	Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 413-423.	0.7	91
120	Intentional portal pressure control is key to improving the outcome of living donor liver transplantation: the Kyoto University Hospital experience. <i>Clinical Transplants</i> , 2008, , 143-9.	0.2	5
121	Living Donor Liver Transplantation for Patients with HCC Exceeding the Milan Criteria: A Proposal of Expanded Criteria. <i>Digestive Diseases</i> , 2007, 25, 299-302.	0.8	117
122	Impact of human leukocyte antigen mismatching on outcomes of living donor liver transplantation for primary biliary cirrhosis. <i>Liver Transplantation</i> , 2007, 13, 80-90.	1.3	53
123	Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. <i>Liver Transplantation</i> , 2007, 13, 1637-1644.	1.3	226
124	Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 90-102.	2.3	50
125	Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 331-345.	2.3	93
126	Long-Term Outcome of Adult-to-Adult Living Donor Liver Transplantation for Post-Kasai Biliary Atresia. <i>American Journal of Transplantation</i> , 2006, 6, 2443-2448.	2.6	41

#	ARTICLE	IF	CITATIONS
127	Surgical Techniques and Long-Term Outcomes of Living Donor Liver Transplantation for Budd-Chiari Syndrome. <i>American Journal of Transplantation</i> , 2006, 6, 2463-2469.	2.6	57
128	Cyclosporine exposure and calcineurin phosphatase activity in living-donor liver transplant patients: Twice daily vs. once daily dosing. <i>Liver Transplantation</i> , 2006, 12, 292-300.	1.3	22
129	Classification of human liver transplant recipients by their preoperative CD8+ T cell subpopulation and its relation to outcome. <i>Liver Transplantation</i> , 2006, 12, 792-800.	1.3	18
130	Quantitative survival model for short-term survival after adult-to-adult living donor liver transplantation. <i>Liver Transplantation</i> , 2006, 12, 904-911.	1.3	13
131	Long-term outcomes of 600 living donor liver transplants for pediatric patients at a single center. <i>Liver Transplantation</i> , 2006, 12, 1326-1336.	1.3	106
132	Delayed Effect of Grapefruit Juice on Pharmacokinetics and Pharmacodynamics of Tacrolimus in a Living-Donor Liver Transplant Recipient. <i>Drug Metabolism and Pharmacokinetics</i> , 2006, 21, 122-125.	1.1	35
133	Variations in Biliary Anatomy Associated with Trifurcated Portal Vein in Right-Lobe Living-Donor Liver Transplantation. <i>Transplantation</i> , 2005, 79, 626-627.	0.5	15
134	Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplant patients. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 78, 168-181.	2.3	75
135	Auxiliary Partial Orthotopic Living Donor Liver Transplantation: Kyoto University Experience. <i>American Journal of Transplantation</i> , 2005, 5, 558-565.	2.6	89
136	Impact of Right Lobe with Middle Hepatic Vein Graft in Living-Donor Liver Transplantation. <i>American Journal of Transplantation</i> , 2005, 5, 1339-1346.	2.6	97
137	IFN-gamma, Produced by NK Cells that Infiltrate Liver Allografts Early After Transplantation, Links the Innate and Adaptive Immune Responses. <i>American Journal of Transplantation</i> , 2005, 5, 2094-2103.	2.6	100
138	Living-donor liver transplantation for situs inversus: 2 case reports. <i>Journal of Pediatric Surgery</i> , 2005, 40, E35-E37.	0.8	14
139	Successful liver transplantation for congenital absence of the portal vein complicated by intrapulmonary shunt and brain abscess. <i>Journal of Pediatric Surgery</i> , 2005, 40, e1-e3.	0.8	31
140	Role of Bcl-2 mRNA in Homeostatic Proliferation in Circulating T-Cells in Human Liver Transplant Patients after T-Cell Depletion. <i>Journal of Surgical Research</i> , 2005, 127, 123-130.	0.8	3
141	Portal Vein Complications in the Long-Term Course After Pediatric Living Donor Liver Transplantation. <i>Transplantation Proceedings</i> , 2005, 37, 1138-1140.	0.3	91
142	Initial Dosage Adjustment for Oral Administration of Tacrolimus Using the Intestinal MDR1 Level in Living-Donor Liver Transplant Recipients. <i>Transplantation Proceedings</i> , 2005, 37, 1728-1729.	0.3	24
143	Total pancreatectomy for intraductal papillary-mucinous tumor of the pancreas: reappraisal of total pancreatectomy. <i>Hepato-Gastroenterology</i> , 2005, 52, 1585-90.	0.5	10
144	"Small-for-size Graft" and "Small-for-size Syndrome" in Living Donor Liver Transplantation. <i>Yonsei Medical Journal</i> , 2004, 45, 1089.	0.9	87

#	ARTICLE	IF	CITATIONS
145	The Role of Apheresis Therapy in Living Donor Liver Transplantation. Therapeutic Apheresis and Dialysis, 2004, 8, 174-179.	0.4	9
146	Successful Surgical Ligation Under Intraoperative Portal Vein Pressure Monitoring of a Large Portosystemic Shunt Presenting as an Intrapulmonary Shunt: Report of a Case. Surgery Today, 2004, 34, 1049-1052.	0.7	28
147	Living donor liver transplantation: Eastern experiences. Hpb, 2004, 6, 88-94.	0.1	33
148	Subcapsular hematoma after right-lobe living-donor liver transplantation. Journal of Hepato-Biliary-Pancreatic Surgery, 2004, 11, 330-332.	2.0	5
149	End-to-side portocaval shunting for a small-for-size graft in living donor liver transplantation. Liver Transplantation, 2004, 10, 807-810.	1.3	106
150	Functional portal flow competition after auxiliary partial orthotopic living donor liver transplantation in noncirrhotic metabolic liver disease. Journal of Pediatric Surgery, 2004, 39, 1138-1141.	0.8	29
151	Identification, cloning, and characterization of a novel rat natural killer receptor, RNKP30: a molecule expressed in liver allografts. Transplantation, 2004, 77, 121-128.	0.5	13
152	CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics and Genomics, 2004, 14, 471-478.	5.7	182
153	Small-for-size graft in living donor liver transplantation: How far should we go?. Liver Transplantation, 2003, 9, S29-S35.	1.3	219
154	A case of inflammatory pseudotumor of the liver hilum successfully treated with aggressive hepatectomy. Journal of Pediatric Surgery, 2003, 38, E9-E11.	0.8	14
155	Monosegmental living-donor liver transplantation for infantile hepatic hemangioendothelioma. Journal of Pediatric Surgery, 2003, 38, 1108-1111.	0.8	34
156	Monosegmental living donor liver transplantation. Transplantation Proceedings, 2003, 35, 1425-1426.	0.3	23
157	Outcomes for pediatric liver retransplantation from living donors. Transplantation, 2003, 76, 943-948.	0.5	33
158	SURGERY-RELATED MORBIDITY IN LIVING DONORS OF RIGHT-LOBE LIVER GRAFT. Transplantation, 2003, 76, 158-163.	0.5	119
159	Changes in portal venous pressure in the early phase after living donor liver transplantation: pathogenesis and clinical implications ^{1,2} . Transplantation, 2003, 75, 1313-1317.	0.5	239
160	Living-related liver transplantation for alagille syndrome. Transplantation, 2003, 75, 2147-2150.	0.5	60
161	Living-donor liver transplantation with monosegments. Transplantation, 2003, 76, 694-696.	0.5	97
162	Role of HLA compatibility in pediatric living-related liver transplantation ¹ . Transplantation, 2002, 74, 1175-1180.	0.5	38

#	ARTICLE	IF	CITATIONS
163	Complete withdrawal of immunosuppression in living donor liver transplantation. Transplantation Proceedings, 2002, 34, 1521.	0.3	42
164	NK cells and transplantation. Transplant Immunology, 2002, 9, 111-114.	0.6	37
165	A case of adult-to-adult living donor liver transplantation using right and left lateral lobe grafts from 2 donors. Surgery, 2002, 131, 682-684.	1.0	26
166	Apheresis Therapy for Living Donor Liver Transplantation. Therapeutic Apheresis and Dialysis, 2002, 6, 478-483.	0.6	22
167	APOPTOSIS AND ALLOGRAFT REJECTION IN THE ABSENCE OF CD8+ T CELLS ¹ . Transplantation, 2001, 71, 1827-1834.	0.5	33
168	Radiolabeled Annexin V Imaging: Diagnosis of Allograft Rejection in an Experimental Rodent Model of Liver Transplantation. Radiology, 2000, 214, 795-800.	3.6	51
169	Treatment of ornithine transcarbamylase deficiency in girls by auxiliary liver transplantation: Conceptual changes in a living-donor program. Journal of Pediatric Surgery, 1998, 33, 1753-1756.	0.8	35
170	Heterogeneous policy effects on the export of photovoltaic and wind energy components: Evidence from a matching estimator. SSRN Electronic Journal, 0, , .	0.4	0